• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sotatercept as a next-generation therapy for pulmonary arterial hypertension: insights from the STELLAR trial.

作者信息

Kopeć Grzegorz

机构信息

Pulmonary Circulation Centre, Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, Prądnicka 80, 31-202 Kraków, Poland.

Department of Cardiac and Vascular Diseases, John Paul II Hospital in Krakow, Prądnicka 80, 31-202 Kraków, Poland.

出版信息

Cardiovasc Res. 2023 Dec 19;119(16):e155-e157. doi: 10.1093/cvr/cvad121.

DOI:10.1093/cvr/cvad121
PMID:37584249
Abstract
摘要

相似文献

1
Sotatercept as a next-generation therapy for pulmonary arterial hypertension: insights from the STELLAR trial.索他洛尔作为肺动脉高压的新一代治疗方法：来自STELLAR试验的见解。
Cardiovasc Res. 2023 Dec 19;119(16):e155-e157. doi: 10.1093/cvr/cvad121.
2
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.索他洛尔治疗肺动脉高压的3期试验
N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6.
3
Sotatercept for the Treatment of Pulmonary Arterial Hypertension.索他拉特塞治疗肺动脉高压。
N Engl J Med. 2021 Apr 1;384(13):1204-1215. doi: 10.1056/NEJMoa2024277.
4
Unsolved Issues on Beneficial Effects of Combination Therapy With Sotatercept in Pulmonary Arterial Hypertension.司他西普联合治疗肺动脉高压有益作用的未解决问题
Heart Lung Circ. 2024 Jan;33(1):12-13. doi: 10.1016/j.hlc.2023.10.010. Epub 2023 Nov 30.
5
Using Sotatercept in the Care of Patients With Pulmonary Arterial Hypertension.使用 Sotatercept 治疗肺动脉高压患者。
Chest. 2024 Sep;166(3):604-611. doi: 10.1016/j.chest.2024.06.3801. Epub 2024 Jul 14.
6
Sotatercept for pulmonary arterial hypertension: something old and something new.索他洛尔治疗肺动脉高压：既有旧法又有新招。
Eur Respir J. 2023 Jan 6;61(1). doi: 10.1183/13993003.01972-2022. Print 2023 Jan.
7
Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH).人口健康模型预测 Sotatercept 对肺动脉高压（PAH）患者发病率和死亡率的长期影响。
Adv Ther. 2024 Jan;41(1):130-151. doi: 10.1007/s12325-023-02684-x. Epub 2023 Oct 18.
8
Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting.索他拉特塞治疗住院患者的肺动脉高压。
J Cardiovasc Pharmacol Ther. 2024 Jan-Dec;29:10742484231225310. doi: 10.1177/10742484231225310.
9
Sotatercept: First Approval.索特西普特：首次批准。
Drugs. 2024 Jul;84(7):857-862. doi: 10.1007/s40265-024-02058-9. Epub 2024 Jun 21.
10
Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?索他拉特塞（一种可捕获激活素和生长分化因子的药物）能否成为肺动脉高压（PAH）治疗的新曙光？
Expert Opin Biol Ther. 2023 Jul-Dec;23(7):589-593. doi: 10.1080/14712598.2023.2221784. Epub 2023 Jun 7.

引用本文的文献

1
Therapeutic challenges and new therapeutic targets for combined capillary pulmonary hypertension: a review.联合性毛细血管前性肺动脉高压的治疗挑战与新治疗靶点：综述
Front Med (Lausanne). 2025 May 2;12:1579112. doi: 10.3389/fmed.2025.1579112. eCollection 2025.
2
Sotatercept and pulmonary arterial hypertension.索他洛尔与肺动脉高压。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024;49(9):1503-1508. doi: 10.11817/j.issn.1672-7347.2024.240093.
3
The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil.
在使用曲前列尼尔治疗肺动脉高压中剂量递增的重要性
Biomedicines. 2025 Jan 13;13(1):172. doi: 10.3390/biomedicines13010172.
4
Connexin43, A Promising Target to Reduce Cardiac Arrhythmia Burden in Pulmonary Arterial Hypertension.缝隙连接蛋白 43：降低肺动脉高压性心律失常负担的有前途靶点
Int J Mol Sci. 2024 Mar 14;25(6):3275. doi: 10.3390/ijms25063275.